Alexia T. Sánchez-Reyes

Alexia T. Sánchez-Reyes

Auto-generated profile, based on publicly available information

Alexia T. Sánchez-Reyes

Neurodegenerative Diseases Unit; School of Medicine Universidad Fernando Pessoa Canarias (UFPC) Santa María de Guía Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SGSophie Glendinning
Sophie Glendinning
JAJosé M. Arbelo
José M. Arbelo
LDLola Díaz-Feliz
Lola Díaz-Feliz
RZRocío Malo de Molina Zamora
Rocío Malo de Molina Zamora
SGSara Gomes
Sara Gomes
OLOswaldo Lorenzo-Betancor
Oswaldo Lorenzo-Betancor
Background: The VPS35 p.D620N variant causes autosomal dominant Parkinson’s disease (PD) and has been shown to activate the LRRK2 kinase pathway, resulting in increased Rab substrate phosphorylation in peripheral immune cells and elevated urinary bis(monoacylglycero)phosphate (BMP) levels. Recently, a VPS35 variant of unknown significance (c.959C>T; p.A320V) was described in two late-onset sporadic PD patients. Methods: We ascertained a family from the Canary Islands in which six siblings were chronically exposed to high doses of pesticides. Three siblings developed levodopa-responsive, akinetic-rigid PD, while the other three remained unaffected. Whole-exome sequencing was performed in the three affected siblings. The frequency of the resulting candidate variant was assessed in 23,327 PD patients and 9,235 controls from four independent cohorts. Members of this pedigree and unrelated controls were assessed for LRRK2 kinase activity in monocytes and neutrophils and BMP levels in urine. Results: The three affected siblings were all heterozygous for p.A320V, whereas the three unaffected siblings did not carry the variant. In the combined PD case-control cohort, p.A320V was identified in six patients and one control. However, unlike p.D620N, heterozygous carrier status for p.A320V was not associated with increased LRRK2 kinase activity or elevated urine BMP levels. Conclusions: While VPS35 p.A320V co-segregated with PD in this family, it did not exhibit the characteristic LRRK2-associated biomarker signature observed in VPS35 p.D620N carriers. It is possible that p.A320V exerts a subtle effect on VPS35 function that was not captured by the assays performed and that chronic pesticide exposure contributed to disease penetrance in this pedigree.

24 September 2026 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
LDLola Díaz‐Feliz
Lola Díaz‐Feliz
Marcos Faundez-ZanuyMarcos Faundez-Zanuy
Marcos Faundez-Zanuy
AGAndrea Gennari
Andrea Gennari
ASAlexia Sánchez‐Reyes
Alexia Sánchez‐Reyes
PSPilar Sanz‐Cartagena
Pilar Sanz‐Cartagena
PGPedro García‐Ruiz
Pedro García‐Ruiz
Background: Digital handwriting distinguishes PD patients from healthy controls but is rarely assessed quantitatively. Objectives: To evaluate digital handwriting as an objective tool to assess motor impairment, dopaminergic response, and progression in PD. Methods: Participants (Healthy Controls, n = 52; De Novo PD Patients assessed at baseline and after 7 weeks, n = 50; PD Patients in OFF–ON states following inhaled levodopa, n = 26; PD Progression Patients, n = 60) wrote a standard sentence on a digitizing tablet. Results: De Novo PD Patients showed reduced handwriting speed and increased in‐air time. Acute dopaminergic stimulation in OFF–ON states was associated with shorter in‐surface and in‐air time. Longer disease duration was associated with increased variability in speed and acceleration. Higher MDS‐UPDRS Part III scores were associated with lower speed and acceleration. Conclusions: Digital handwriting is an objective digital biomarker for quantifying PD dysgraphia and its response to dopaminergic treatment.